Evidence map›Paper›PMID 28778650›Full record

ReviewGastroenterology2018

Endoscopic Management of Early Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus: Screening, Diagnosis, and Therapy.

Massimiliano di Pietro, Marcia I Canto, Rebecca C Fitzgerald

Registry-linked trialAbstract readReview
In one paragraph

Review in Gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05680077 (Methylation Detection of KCNA3 and OTOP2 Genes in Plasma for the Auxiliary Diagnosis of Esophageal Cancer/Precancerous Lesions), which is not on this map. Cited by 130 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
130citing papers in PubMed, 4 pooled it
14.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05680077 completednot on this mapstarted 2022, after this paper: background citation

Methylation Detection of KCNA3 and OTOP2 Genes in Plasma for the Auxiliary Diagnosis of Esophageal Cancer/Precancerous Lesions: a Clinical Trial

Typeobservational_patient_registrySponsorWuhan Ammunition Life-tech Co., LtdRan2022 to 2023Enrolled1,116ConditionsEsophageal NeoplasmsArmsKCNA3 and OTOP2 Gene Methylation Combined Detection Kit (Fluorescent PCR Method)
3 · Its place in the literature

Who cites it

130 citing papers in PubMed, 4 syntheses or guidelines pooled it, 252 citations in OpenAlex.

  1. Endoscopic resection versus esophagectomy for T1bN0M0 esophageal cancer: a systematic review and meta-analysis.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

70 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Massimiliano di PietroMRC Cancer Unit, University of Cambridge, Cambridge, United Kingdom.
Marcia I CantoDivision of Gastroenterology and Hepatology, Johns Hopkins Medical Institutions, Baltimore, Maryland.
Rebecca C FitzgeraldMRC Cancer Unit, University of Cambridge, Cambridge, United Kingdom.
Johns Hopkins University · USMRC Cancer Unit · GBUniversity of Cambridge · GB

Funding

Medical Research Council MC_UU_12022/2
6 · The paper itself

Abstract

Because the esophagus is easily accessible with endoscopy, early diagnosis and curative treatment of esophageal cancer is possible. However, diagnosis is often delayed because symptoms are not specific during early stages of tumor development. The onset of dysphagia is associated with advanced disease, which has a survival at 5 years lower than 15%. Population screening by endoscopy is not cost-effective, but a number of alternative imaging and cell analysis technologies are under investigation. The ideal screening test should be inexpensive, well tolerated, and applicable to primary care. Over the past 10 years, significant progress has been made in endoscopic diagnosis and treatment of dysplasia (squamous and Barrett's), and early esophageal cancer using resection and ablation technologies supported by evidence from randomized controlled trials. We review the state-of-the-art technologies for early diagnosis and minimally invasive treatment, which together could reduce the burden of disease.

Indexed as

Ablation TechniquesAdenocarcinomaBarrett EsophagusBiomarkers, TumorBiopsyBreath TestsCapsule EndoscopyCarcinoma, Squamous CellColoring AgentsEarly Detection of CancerEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaEsophagectomyEsophagoscopyEsophagusHumansBiomarkers, TumorColoring AgentsBarrett’s EsophagusEndoscopyEsophageal CancerScreening

Identifiers

PMID28778650
PMCPMC6104810
OpenAlexW2741747320

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.